JP2019522050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522050A5 JP2019522050A5 JP2019518185A JP2019518185A JP2019522050A5 JP 2019522050 A5 JP2019522050 A5 JP 2019522050A5 JP 2019518185 A JP2019518185 A JP 2019518185A JP 2019518185 A JP2019518185 A JP 2019518185A JP 2019522050 A5 JP2019522050 A5 JP 2019522050A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- antibody
- antigen
- binding fragment
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022116511A JP2022163075A (ja) | 2016-06-17 | 2022-07-21 | 細胞の枯渇のための組成物および方法 |
| JP2023208327A JP2024037832A (ja) | 2016-06-17 | 2023-12-11 | 細胞の枯渇のための組成物および方法 |
| JP2026004999A JP2026086439A (ja) | 2016-06-17 | 2026-01-15 | 細胞の枯渇のための組成物および方法 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351778P | 2016-06-17 | 2016-06-17 | |
| US201662351725P | 2016-06-17 | 2016-06-17 | |
| US62/351,778 | 2016-06-17 | ||
| US62/351,725 | 2016-06-17 | ||
| US201662437729P | 2016-12-22 | 2016-12-22 | |
| US201662437756P | 2016-12-22 | 2016-12-22 | |
| US62/437,729 | 2016-12-22 | ||
| US62/437,756 | 2016-12-22 | ||
| US201762448782P | 2017-01-20 | 2017-01-20 | |
| US201762448768P | 2017-01-20 | 2017-01-20 | |
| US62/448,782 | 2017-01-20 | ||
| US62/448,768 | 2017-01-20 | ||
| PCT/US2017/038151 WO2017219025A1 (en) | 2016-06-17 | 2017-06-19 | Compositions and methods for the depletion of cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022116511A Division JP2022163075A (ja) | 2016-06-17 | 2022-07-21 | 細胞の枯渇のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019522050A JP2019522050A (ja) | 2019-08-08 |
| JP2019522050A5 true JP2019522050A5 (enExample) | 2020-07-30 |
Family
ID=60664586
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518185A Pending JP2019522050A (ja) | 2016-06-17 | 2017-06-19 | 細胞の枯渇のための組成物および方法 |
| JP2022116511A Pending JP2022163075A (ja) | 2016-06-17 | 2022-07-21 | 細胞の枯渇のための組成物および方法 |
| JP2023208327A Pending JP2024037832A (ja) | 2016-06-17 | 2023-12-11 | 細胞の枯渇のための組成物および方法 |
| JP2026004999A Pending JP2026086439A (ja) | 2016-06-17 | 2026-01-15 | 細胞の枯渇のための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022116511A Pending JP2022163075A (ja) | 2016-06-17 | 2022-07-21 | 細胞の枯渇のための組成物および方法 |
| JP2023208327A Pending JP2024037832A (ja) | 2016-06-17 | 2023-12-11 | 細胞の枯渇のための組成物および方法 |
| JP2026004999A Pending JP2026086439A (ja) | 2016-06-17 | 2026-01-15 | 細胞の枯渇のための組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20190328901A1 (enExample) |
| EP (1) | EP3471772A4 (enExample) |
| JP (4) | JP2019522050A (enExample) |
| KR (3) | KR20260118554A (enExample) |
| CN (1) | CN109641051A (enExample) |
| AU (3) | AU2017204139B2 (enExample) |
| BR (1) | BR112018076263A2 (enExample) |
| CA (1) | CA3028145A1 (enExample) |
| IL (1) | IL263743A (enExample) |
| MA (1) | MA45407A (enExample) |
| MX (1) | MX2018015683A (enExample) |
| SG (1) | SG11201811292RA (enExample) |
| WO (1) | WO2017219025A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109562164B (zh) | 2016-04-04 | 2022-10-04 | 海默珍科医药有限责任公司 | 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法 |
| CA3070242A1 (en) | 2017-07-18 | 2019-01-24 | Calimmune, Inc. | Compositions and methods for treating beta-hemoglobinopathies |
| AU2018374283B2 (en) | 2017-11-29 | 2025-09-18 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD5+ cells |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| CA3098103A1 (en) * | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| JP2021530545A (ja) * | 2018-07-23 | 2021-11-11 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 同種異系の細胞療法における抗−ｃｄ２抗体薬物コンジュゲート（ａｄｃ）の使用 |
| EP3826625A4 (en) * | 2018-07-23 | 2022-08-24 | Magenta Therapeutics, Inc. | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY |
| AU2019370367A1 (en) | 2018-10-30 | 2021-06-17 | Magenta Therapeutics, Inc. | Anti-CD45 antibodies and conjugates thereof |
| AU2019374055B2 (en) * | 2018-10-30 | 2026-06-11 | Regeneron Pharmaceuticals, Inc. | Methods for allogeneic hematopoietic stem cell transplantation |
| CN113518825A (zh) | 2018-12-23 | 2021-10-19 | 美国杰特贝林生物制品有限公司 | Wiskott-aldrich综合征的造血干细胞基因疗法 |
| JP2022518150A (ja) * | 2019-01-07 | 2022-03-14 | マジェンタ セラピューティクス インコーポレイテッド | 細胞療法での抗ｃｄ４５抗体－薬物結合体（ａｄｃ）の使用経験 |
| WO2020219959A1 (en) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Anti-cd45 antibody drug conjugates and uses thereof |
| EP3958878A4 (en) * | 2019-04-24 | 2022-12-28 | Magenta Therapeutics, Inc. | CONDITIONING METHODS FOR GENE THERAPY |
| EP3958879A4 (en) * | 2019-04-25 | 2023-05-10 | Actinium Pharmaceuticals, Inc. | Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases |
| AU2020289360A1 (en) * | 2019-06-04 | 2022-01-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune diseases |
| CN114245807B (zh) * | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| TWI877179B (zh) * | 2019-06-27 | 2025-03-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
| WO2021007266A1 (en) * | 2019-07-09 | 2021-01-14 | Hemogenyx Llc | Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies |
| JP2022543779A (ja) * | 2019-07-30 | 2022-10-14 | デンドロサイト バイオテック ピーティーワイ リミテッド | イムノコンジュゲート |
| AU2020376934A1 (en) * | 2019-11-01 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Anti-CD45 antibodies and conjugates thereof |
| KR20220154676A (ko) * | 2020-02-18 | 2022-11-22 | 마젠타 테라퓨틱스 인코포레이티드 | 동종 이식을 위한 조성물 및 방법 |
| US20230158104A1 (en) * | 2020-03-02 | 2023-05-25 | Pharma Mar, S.A. | Compounds for use in autoimmune conditions |
| US12496303B2 (en) | 2020-10-19 | 2025-12-16 | Washington University | Conditioning agents for use in allogeneic hematopoietic stem cell transplantation |
| CA3240875A1 (en) | 2021-12-23 | 2023-06-29 | Stefanie Urlinger | Discernible cell surface protein variants of cd45 for use in cell therapy |
| WO2025213182A1 (en) * | 2024-04-05 | 2025-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Combinatorial approaches for targeting hematopoietic cells |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074650A (en) | 1985-06-24 | 2000-06-13 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses |
| WO1990009799A1 (en) | 1989-02-23 | 1990-09-07 | Colorado State University Research Foundation | GnRH ANALOGS FOR DESTROYING GONADOTROPHS |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6106834A (en) | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
| US6024957A (en) | 1993-06-02 | 2000-02-15 | Research Corporation Technologies, Inc. | Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same |
| GB9323199D0 (en) | 1993-11-10 | 1994-01-05 | Falkenberg J H F | Leukaemia treatment |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| US20110045005A1 (en) | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US7265212B2 (en) | 2001-12-03 | 2007-09-04 | Amgen Fremont Inc. | Anti-CD45RB antibodies |
| DE602004026081D1 (de) * | 2003-09-18 | 2010-04-29 | Novartis Ag | Therapeutische humanisierte antikörper gegen cd45-isoformen |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| EP1661584A1 (en) | 2004-11-26 | 2006-05-31 | Heinz Dr. Faulstich | Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy |
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| WO2007087453A2 (en) | 2006-01-27 | 2007-08-02 | Cellerant Therapeutics, Inc. | Compositions and methods for treating haematological proliferative disorders |
| EP1993608A1 (en) | 2006-03-10 | 2008-11-26 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| ATE521366T1 (de) | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen |
| PT2032606E (pt) | 2006-05-30 | 2014-02-05 | Genentech Inc | Anticorpos e imunoconjugados e respetivas utilizações |
| WO2008045976A2 (en) * | 2006-10-10 | 2008-04-17 | Squicor | Compositions and methods for treating and diagnosing cancers |
| EP3255061B1 (en) * | 2006-11-03 | 2021-06-16 | The Board of Trustees of the Leland Stanford Junior University | Selective immunodepletion of endogenous stem cell niche for engraftment |
| PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| PE20120877A1 (es) * | 2009-04-01 | 2012-08-06 | Genentech Inc | ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS |
| MX2011010469A (es) | 2009-04-08 | 2012-03-14 | Deutsches Krebsforsch | Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer. |
| EP3192529B1 (en) * | 2009-04-08 | 2020-03-25 | Faulstich, Heinz, Dr. | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
| CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| ES2402254T3 (es) | 2010-09-30 | 2013-04-30 | Heidelberg Pharma Ag | Conjugados de amatoxinas con ligadores mejorados |
| EP2497499A1 (en) * | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
| WO2012129514A1 (en) * | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| DK2707031T3 (da) | 2011-05-08 | 2019-10-07 | Legochem Biosciences Inc | Protein-active agent conjugates and method for preparing the same |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| CA2850264C (en) | 2011-10-14 | 2019-11-05 | Medimmune Limited | Pyrrolobenzodiazepines |
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| EP2684865A1 (en) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
| US20150218220A1 (en) | 2012-09-12 | 2015-08-06 | Brian Alan MENDELSOHN | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
| US9324898B2 (en) * | 2012-09-25 | 2016-04-26 | Alliance For Sustainable Energy, Llc | Varying cadmium telluride growth temperature during deposition to increase solar cell reliability |
| AU2013350802B2 (en) * | 2012-11-30 | 2016-07-14 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
| WO2014134539A1 (en) | 2013-02-28 | 2014-09-04 | President And Fellows Of Harvard College | Methods and compositions for mobilizing stem cells |
| EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| EP2968591A1 (en) * | 2013-03-15 | 2016-01-20 | Novartis AG | Cell proliferation inhibitors and conjugates thereof |
| US9803002B2 (en) | 2013-05-31 | 2017-10-31 | Genentench, Inc. | Anti-wall teichoic antibodies and conjugates |
| US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| CN110251683A (zh) | 2013-06-24 | 2019-09-20 | Abl生物公司 | 具有改进的稳定性的抗体-药物缀合物及其用途 |
| FR3008408B1 (fr) | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
| CN105377304B (zh) * | 2014-03-10 | 2018-05-15 | 海德堡医药有限责任公司 | 鹅膏毒肽衍生物 |
| WO2015187596A2 (en) | 2014-06-02 | 2015-12-10 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| US20170226209A1 (en) * | 2014-08-01 | 2017-08-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An anti-cd45rc antibody for use as drug |
| RU2715905C2 (ru) | 2014-10-01 | 2020-03-04 | МЕДИММЬЮН, ЭлЭлСи | Способ конъюгации полипептида |
| US20190209704A1 (en) | 2014-10-20 | 2019-07-11 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions and methods of use |
| EP3215519A1 (en) * | 2014-11-06 | 2017-09-13 | Novartis AG | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
| EP3026060A1 (en) * | 2014-11-26 | 2016-06-01 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for CD45R0 |
| US9729129B2 (en) * | 2014-12-05 | 2017-08-08 | Bhaskar Gopalan | System and method for reducing metastability in CMOS flip-flops |
| US20160220687A1 (en) | 2015-02-02 | 2016-08-04 | National Guard Health Affairs | Metalloproteinase-cleavable alpha-amanitin-dendrimer conjugates and method of treating cancer |
| DK3268047T3 (da) | 2015-03-09 | 2024-01-02 | Heidelberg Pharma Res Gmbh | Amatoxin/antistof-konjugater |
| HK1256681A1 (zh) * | 2015-04-06 | 2019-10-04 | President And Fellows Of Harvard College | 用於非清髓性预处理的组合物和方法 |
| JP6880005B2 (ja) | 2015-05-21 | 2021-06-02 | アクティニウム ファーマシューティカルズ インコーポレイテッド | 結合型モノクローナル抗体の注入投与 |
| WO2017051249A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| US10723766B2 (en) | 2015-11-27 | 2020-07-28 | Heidelberg Pharma Research Gmbh | Derivatives of gamma-amanitin |
| EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| CA3016901C (en) | 2016-03-07 | 2023-06-13 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
| MX2018012803A (es) | 2016-04-20 | 2019-06-24 | Hangzhou Dac Biotech Co Ltd | Derivados de las toxinas de amanita y su conjugacion a una molecula de union celular. |
| US10464969B2 (en) | 2016-05-05 | 2019-11-05 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
| EP3464363A1 (en) | 2016-05-27 | 2019-04-10 | Actinium Pharmaceuticals, Inc. | Low dose antibody-based methods for treating hematologic malignancies |
| US11013816B2 (en) | 2016-05-31 | 2021-05-25 | Sorrento Therapeutics, Inc. | Antibody drug conjugates having derivatives of amatoxin as the drug |
| US10111966B2 (en) | 2016-06-17 | 2018-10-30 | Magenta Therapeutics, Inc. | Methods for the depletion of CD117+ cells |
| CN110023489A (zh) | 2016-08-29 | 2019-07-16 | Pdi医药发展国际股份公司 | 提供治疗活性细胞产物 |
| US10112266B2 (en) * | 2016-09-09 | 2018-10-30 | Baltic Innovation Holding PRO, AS | Pressed thermite rod for a self-contained portable cutting device |
| WO2018071871A1 (en) * | 2016-10-13 | 2018-04-19 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
| BR112019012937A2 (pt) | 2016-12-23 | 2019-12-10 | Heidelberg Pharma Research Gmbh | novo conjugado de amanitina |
| SG11201906319XA (en) | 2017-01-20 | 2019-08-27 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd137+ cells |
| IL301075B2 (en) | 2017-01-30 | 2024-05-01 | Univ Leland Stanford Junior | A genotoxic matching regimen for stem cell transplantation |
| CN110997676B (zh) | 2017-08-07 | 2022-12-20 | 海德堡医药研究有限责任公司 | 合成鹅膏蕈碱的新方法 |
-
2017
- 2017-06-19 CN CN201780050855.7A patent/CN109641051A/zh active Pending
- 2017-06-19 AU AU2017204139A patent/AU2017204139B2/en active Active
- 2017-06-19 KR KR1020267024157A patent/KR20260118554A/ko active Pending
- 2017-06-19 MX MX2018015683A patent/MX2018015683A/es unknown
- 2017-06-19 JP JP2019518185A patent/JP2019522050A/ja active Pending
- 2017-06-19 BR BR112018076263-6A patent/BR112018076263A2/pt not_active IP Right Cessation
- 2017-06-19 SG SG11201811292RA patent/SG11201811292RA/en unknown
- 2017-06-19 EP EP17814261.8A patent/EP3471772A4/en active Pending
- 2017-06-19 US US16/310,738 patent/US20190328901A1/en not_active Abandoned
- 2017-06-19 KR KR1020197001536A patent/KR20190039085A/ko not_active Ceased
- 2017-06-19 WO PCT/US2017/038151 patent/WO2017219025A1/en not_active Ceased
- 2017-06-19 MA MA045407A patent/MA45407A/fr unknown
- 2017-06-19 CA CA3028145A patent/CA3028145A1/en active Pending
- 2017-06-19 KR KR1020237017708A patent/KR20230082055A/ko not_active Ceased
-
2018
- 2018-07-27 AU AU2018208749A patent/AU2018208749B2/en active Active
- 2018-12-16 IL IL263743A patent/IL263743A/en unknown
-
2019
- 2019-02-28 US US16/289,388 patent/US10624973B2/en active Active
-
2020
- 2020-04-20 US US16/853,619 patent/US20200376134A1/en not_active Abandoned
- 2020-08-11 AU AU2020217338A patent/AU2020217338A1/en not_active Abandoned
-
2022
- 2022-07-21 JP JP2022116511A patent/JP2022163075A/ja active Pending
-
2023
- 2023-11-03 US US18/501,451 patent/US20240207428A1/en not_active Abandoned
- 2023-12-11 JP JP2023208327A patent/JP2024037832A/ja active Pending
-
2024
- 2024-03-14 US US18/605,123 patent/US20240408168A1/en active Pending
-
2026
- 2026-01-15 JP JP2026004999A patent/JP2026086439A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019108863A4 (en) | Compositions and methods for the depletion of cd5+ cells | |
| JP2021500391A5 (enExample) | ||
| WO2019084064A4 (en) | Compositions and methods for the depletion of cd117+ cells | |
| JP2019522680A5 (enExample) | ||
| CN110461876B (zh) | 用于耗尽cd137+细胞的组合物和方法 | |
| US11384148B2 (en) | Anti-FcRn antibodies | |
| WO2019108860A4 (en) | Compositions and methods for the depletion of cd2+ cells | |
| KR102236259B1 (ko) | 항-lag-3 항체 및 그것의 사용 | |
| ES2649155T3 (es) | Anticuerpos anti-OX40 y procedimientos de uso de los mismos | |
| JP2020513791A5 (enExample) | ||
| JP6998857B2 (ja) | Ｃｄ７９に結合する抗体分子 | |
| JP2021519295A (ja) | 抗ｃｄ３８抗体の皮下投薬 | |
| JP2021504414A5 (enExample) | ||
| KR20180119653A (ko) | Tigit에 대한 항체 | |
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| RU2012142311A (ru) | Интерлейкин-13-связывающие белки | |
| JP2019522050A (ja) | 細胞の枯渇のための組成物および方法 | |
| RU2015118180A (ru) | Антитела к бета-амилоиду | |
| WO2013072523A4 (en) | Bi-specific antibodies for medical use | |
| TW201902925A (zh) | 抗cd40抗體、其抗原結合片段及其醫藥用途 | |
| JP2023520399A5 (enExample) | ||
| KR20220030934A (ko) | 항-gal9 면역-억제 결합 분자 | |
| CN110343180B (zh) | 抗ctla-4抗体及其应用 | |
| EP3959242A1 (en) | Anthracycline antibody-drug conjugates and uses thereof | |
| CN114206358A (zh) | T细胞消耗疗法 |